Brii Bio Reports Phase 2 Progress in Hepatitis B Cure
Durham, North Carolina, USA, and Beijing, China, November 6, 2026 Brii Biosciences (Brii Bio) has announced encouraging end-of-treatment and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Durham, North Carolina, USA, and Beijing, China, November 6, 2026 Brii Biosciences (Brii Bio) has announced encouraging end-of-treatment and...
DURHAM, North Carolina & BEIJING, China, July 3, 2026 Brii Biosciences Limited (Brii Bio) has announced positive topline end-of-treatment...
